CMS Issues Permanent J-Codes for Xipere, Susvimo, Vyvgart

The Centers for Medicare and Medicaid Services issued permanent J-codes for three ophthalmic products in the first quarter of 2022. The codes take effect July 1.

They are part of the Healthcare Common Procedure Coding System (HCPCS) and are used to report medical procedures to Medicare, Medicaid, and several other third-party payers.

J-codes identify injectable drugs ordinarily not self-administered, chemotherapy drugs, and some orally administered drugs.

Xipere

Bausch + Lomb’s Xipere received permanent J-code J3299, “Injection, triamcinolone acetonide (Xipere), 1 mg.”

Xipere is an injectable suspension of triamcinolone acetonide, a synthetic corticosteroid for use with the SCS Microinjector, for suprachoroidal use in the treatment of macular edema associated with uveitis.

Susvimo

Genentech/Roche’s Susvimo received J-code J2779, "Injection, ranibizumab, via intravitreal implant (Susvimo), 0.1 mg."

The Susvimo intraocular drug delivery system consists of an implant and ancillary devices to fill, insert, and explant (if needed) the implant. Susvimo, a VEGF inhibitor, is indicated for the treatment of patients with wet age-related macular degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor.

Vyvgart

Argenx' Vyvgart received permanent J-code J9332, “Injection, efgartigimod alfa-fcab, 2 mg.”

Vyvgart, given as a once-weekly infusion for four weeks, is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.